Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma  by Crescenzo, Ramona et al.
ArticleConvergent Mutations and Kinase Fusions Lead to
Oncogenic STAT3 Activation in Anaplastic Large Cell
LymphomaGraphical AbstractHighlightsd Co-occurring somaticmutations of JAK1 and STAT3 promote
oncogenesis
d Novel chimera fuse transcription/repressor domains to
tyrosine kinases (TKs)
d Dual functional TK fusions are oncogenic andmediate STAT3
transformation
d JAK/STAT3 inhibitors have therapeutic efficacy in pre-clinical
ALCL modelsCrescenzo et al., 2015, Cancer Cell 27, 516–532
April 13, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.ccell.2015.03.006Authors
Ramona Crescenzo,
Francesco Abate, ..., Raul Rabadan,
Giorgio Inghirami
Correspondence
rr2579@cumc.columbia.edu (R.R.),
ggi9001@med.cornell.edu (G.I.)
In Brief
Crescenzo et al. provide a
comprehensive characterization of driver
genetic alterations in ALK anaplastic
large cell lymphomas (ALCLs) and
uncover mechanisms leading to the
constitutive activation of STAT3 in ALK
ALCL. JAK/STAT3 inhibitors have
therapeutic efficacy in pre-clinical ALCL
models.Accession NumbersGSE50253
GSE6338
GSE14879
GSE19069
Cancer Cell
ArticleConvergent Mutations and Kinase Fusions
Lead to Oncogenic STAT3 Activation
in Anaplastic Large Cell Lymphoma
Ramona Crescenzo,1,2,27 Francesco Abate,1,3,4,27 Elena Lasorsa,1,27 Fabrizio Tabbo’,1,2 Marcello Gaudiano,1,2
Nicoletta Chiesa,1 Filomena Di Giacomo,1 Elisa Spaccarotella,1 Luigi Barbarossa,1 Elisabetta Ercole,1 Maria Todaro,1,2
Michela Boi,1,2 Andrea Acquaviva,3 Elisa Ficarra,3 Domenico Novero,5 Andrea Rinaldi,6 Thomas Tousseyn,7
Andreas Rosenwald,8 Lukas Kenner,9 Lorenzo Cerroni,10 Alexander Tzankov,11 Maurilio Ponzoni,12 Marco Paulli,13
Dennis Weisenburger,14 Wing C. Chan,14 Javeed Iqbal,15 Miguel A. Piris,16 Alberto Zamo’,17 Carmela Ciardullo,18
Davide Rossi,18 Gianluca Gaidano,18 Stefano Pileri,19,20 Enrico Tiacci,21 Brunangelo Falini,21 Leonard D. Shultz,22
Laurence Mevellec,23 Jorge E. Vialard,24 Roberto Piva,1,25 Francesco Bertoni,6,26 Raul Rabadan,4,*
Giorgio Inghirami,1,2,25,* and The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data
in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium ‘‘Genetics-Driven Targeted Management
of Lymphoid Malignancies’’
1Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies, University of
Torino, 10126 Torino, Italy
2Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10021, USA
3Department of Control and Computer Engineering, Politecnico di Torino, 10129 Torino, Italy
4Department of Biomedical Informatics and Department of Systems Biology, Center for Computational Biology and Bioinformatics, Columbia
University, New York, NY 10027, USA
5Department of Pathology, A.O. Citta` della Salute e della Scienza (Molinette), 10126 Torino, Italy
6Lymphoma and Genomics Research Program, Institute of Oncology Research, 6500 Bellinzona, Switzerland
7Translational Cell and Tissue Research Lab, KU Leuven, 3000 Leuven, Belgium
8Institute of Pathology, University of Wu¨rzburg and Comprehensive Cancer Center Mainfranken, 97080 Wu¨rzburg, Germany
9Ludwing Boltzmann Institute for Cancer Research, 1090 Vienna, Austria
10Research Unit Dermatopathology of the Medical University of Graz, 8036 Graz, Austria
11Institute of Pathology, University Hospital Basel, 4031 Basel, Switzerland
12Pathology & Lymphoid Malignancies Units, San Raffaele Scientific Institute, 20132 Milan, Italy
13Department of Human Pathology, University of Pavia and Scientific Institute Fondazione Policlinico San Matteo, 27100 Pavia, Italy
14Department of Pathology, City of Hope Medical Center, Duarte, CA 91010, USA
15Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA
16Cancer Genomics, Instituto de Formacio´n e Investigacio´n Marque´s de Valdecilla and Department of Pathology, Hospital Universitario
Marque´s de Valdecilla, 39008 Santander, Spain
17Department of Pathology and Diagnostics, University of Verona, 37134 Verona, Italy
18Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, 28100 Novara, Italy
19European Institute of Oncology, 20141 Milano, Italy
20Bologna University School of Medicine, 40126 Bologna, Italy
21Institute of Hematology-Centro di Ricerche Onco-Ematologiche (CREO), Ospedale S. Maria della Misericordia, University of Perugia,
06100 Perugia, Italy
22The Jackson Laboratory, Bar Harbor, ME 04609, USA
23Janssen Research & Development, a Division of Janssen-Cilag, Campus de Maigremont, CS10615, 27106 Val-de-Reuil Cedex, France
24Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
25Department of Pathology and NYU Cancer Center, New York University School of Medicine, New York, NY 10016, USA
26Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
27Co-first author
*Correspondence: rr2579@cumc.columbia.edu (R.R.), ggi9001@med.cornell.edu (G.I.)
http://dx.doi.org/10.1016/j.ccell.2015.03.006Significance
The JAK/STAT3 signaling pathway is often deregulated in hematopoietic disorders. We describe two mechanisms leading
to the constitutive activation of STAT3 in ALK ALCL. Oncogenic JAK1 or STAT3mutations are associated with hyperactive
pSTAT3, which regulates canonical STAT3 and ATF3 genes. Moreover, synergizing JAK1 and STAT3 mutants sustain the
neoplastic growth, which can be efficiently controlled in vitro and in an ALCL patient-derived tumorgraft model by
JAK1/2 inhibitors. We discovered that chimera, displaying concomitant transcriptional and kinase activities, are power on-
cogenes capable to sustain via STAT3 the ALCL phenotype. The pharmacological inhibition of JAK/STAT3 represents an
alternative strategy for the treatment of molecularly stratified ALCL.
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SUMMARYA systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating
massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations
(somatic point mutations, copy number alterations, and gene fusions) in ALK ALCLs. We identified acti-
vating mutations of JAK1 and/or STAT3 genes in 20% of 88 ALK ALCLs and demonstrated that 38% of
systemic ALK ALCLs displayed double lesions. Recurrent chimeras combining a transcription factor
(NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK
ALCL. All these aberrations lead to the constitutive activation of the JAK/STAT3 pathway, which was proved
oncogenic. Consistently, JAK/STAT3 pathway inhibition impaired cell growth in vitro and in vivo.INTRODUCTION
Peripheral T cell lymphomas (PTCLs) are a heterogeneous group
of tumors derived from post-thymic lymphocytes (Swerdlow
et al., 2008). They are orphan diseases, accounting for 12% to
15% of all non-Hodgkin’s lymphoma in Western populations
(Vose et al., 2008), and display great variability in their clinical,
morphological, immunophenotypic, cytogenetic, and molecular
features. The classification of anaplastic large cell lymphomas
(ALCLs) has been revised several times, and ALCLs are nowa-
days designated as a distinct entity of systemic PTCL (Swerdlow
et al., 2008). Meanwhile, cutaneous forms of ALCLs (cALCLs) are
recognized as a different variant. Among systemic ALCLs, pa-
tients harboring translocations of anaplastic lymphoma kinase
(ALK) generally have a more favorable clinical course (Vose
et al., 2008), although aggressive outcomes exist (Grewal
et al., 2007). In contrast, ALKALCL patients have highmorbidity
and mortality, and ALCL remains an incurable disease in 70%
of patients (Savage et al., 2008).
The genetics of ALK+ ALCL is characterized by transloca-
tions of the ALK proto-oncogene leading to ALK fusion pro-
teins. The ALK chimeras activate STAT3, whose deregulated
program is required for the maintenance of the neoplastic
phenotype in ALK+ ALCL (Chiarle et al., 2005). Conversely,
the mechanisms of transformation and maintenance of the
ALK ALCLs remain elusive. Recurrent translocations and
loss of TP53 and PRDM1/BLIMP1 have been proved to have
a pathogenic role associated with less favorable outcomes
(Boi et al., 2013; Parilla Castellar et al., 2014). Last, compara-
tive genomic hybridization studies have shown that ALK+
ALCLs display a more stable genome than ALK ALCL or
cALCL (Boi et al., 2013).
There are several alternative mechanisms leading to hyperac-
tive STAT signaling in human cancers. These include aberrant or
chronic stimulation via cytokines and growth factors, constitu-
tive engagement of wild-type (WT) and mutated RTK receptors,
and deregulated activation of several G protein-coupled recep-
tors. Likewise, STAT3 hyper-activation occurs within multiple
elements of stromal compartment and/or host immune cells,
making STAT3 a central actor for inflammation-induced cancers
(Bournazou and Bromberg, 2013). Disrupting mutations control-
ling epigenetically endogenous regulators of STAT3 (Johnston
and Grandis, 2011) and somatic mutations of STATs, detectable
in rare solid tumors and selected lymphoproliferative disorders,
have been described (Kiel et al., 2014; Koskela et al., 2012; Pilati
et al., 2011). These data validate STAT3 as a valuable therapeutic
target.To characterize the spectrum of mutations in ALK ALCL and
to identify potential therapeutic targets, we used massive
genomic sequencing of both RNA and DNA. We investigated
the landscape of somatic point mutations, copy number alter-
ations, and gene fusions and we infer the associated mutational
mechanisms of disease along with a set of in vitro and in vivo
models.
RESULTS
Whole-Exome Sequencing Somatic Mutation Analyses
Demonstrate the Presence of Recurrent Mutations in
ALK– ALCL
The number of mutations per case varied markedly (mean of
36 non-synonymous somatic mutations, from 1 to 150) without
any preferential chromosomal distribution (Figure 1A). Mutations
were largely represented by single-nucleotide substitutions
leading to amino acid changes, namely, missense mutations
(n = 752 [90%]), but included insertions or deletions (n = 15
[1.8%]), nonsense mutations (n = 63 [7.6%]), and alterations in
canonical splice sites (n = 1 [0.1%]) (Figure S1).
Mutations were identified in PRDM1/BLIMP1, TP53, STAT3,
JAK1, and BANK1 (Figure 1A). Integration of somatic mutations
and focal copy number alterations highlighted PRDM1/BLIMP1,
TP53, and CSMD2 as commonly mutated or deleted genes.
TUBGCP6 and STAT3 genes were shown to be mutated or
amplified (Figure 1B). Next we estimated the statistical signifi-
cance of recurrent mutated genes and identified 13 putative
candidate drivers on the basis of known functions and bio-
informatics prediction (Figure S1, Tables S1 and S2, and Supple-
mental Information); those pathogenic roles require further
functional studies.
Mutations of JAK1 and STAT3 Are Common in ALK–
ALCL
JAK-STAT pathway genes (i.e., STAT3 and JAK1) were recur-
rently mutated in the discovery ALK ALCL panel (Figure S1),
suggesting that a STAT3-mediated oncogenic mechanism may
be shared by all ALCLs, independent of ALK status. To define
the mutation recurrence of JAK/STAT3 genes in ALK ALCL,
we analyzed by targeted re-sequencing the mutation hot spots
of STAT3 (i.e., the SH2 domain) and JAK1-3 (i.e., the kinase
domain [KD]) in a validation panel of PTCL.
A total of 155 primary ALCL samples (88 ALK and 23 ALK+
ALCLs and 44 cALCLs) and 74 PTCLs (29 angioimmuno-
blastic T cell lymphomas, 31 PTCLs not otherwise specified
[PTCL-NOS], and 14 NK-T cell lymphomas) were sequenced.Cancer Cell 27, 516–532, April 13, 2015 ª2015 Elsevier Inc. 517
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Figure 1. Somatic Mutation and STAT3 Expression in ALCL
(A) Circos plot graphical representation of somatic synonymous and non-synonymous SNVs displays the mutational distribution across chromosomes (repre-
sented with different colors). Concentric circles are distinguished by different color background. Mutations are depicted as red points, and the outer circle depicts
the histogram of the mutations per genomic position (red bars over gray background).
(legend continued on next page)
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Non-synonymous somatic mutations of STAT3 and/or JAK1
were identified in 18% of systemic ALK ALCLs and 5% of
cALCLs (Figure 1C). Remarkably, 37.5% of the systemic ALK
ALCL cases harbored mutations of STAT3 and JAK1 (p <
0.0009, Fisher’s exact test). Because Sanger DNA sequencing
detects somatic mutations when mutated alleles are well repre-
sented (>10% of the total), we performed two deep sequencing
strategies (deep sequencing analysis [DSA]; sensitivity down to
0.1%–1%) to detect variants restricted to a small fraction of
the alleles (Figure S1). DSA excluded the occurrence of mutated
subclones in systemic ALK ALCL that lacked STAT3 and JAK1
mutations by Sanger sequencing. cALCLs, characterized by an
indolent clinical course (Savage et al., 2008), were also analyzed
by Sanger sequencing and DSA. By applying both strategies,
cALCLs were found to harbor either JAK1 (6 of 29) or STAT3 (3
of 29) variants, but no co-occurrence of JAK1-STAT3mutations.
In systemic ALK and cutaneous ALCLs, STAT3mutations were
substitutions targeting a hot spot in the SH2 domain, including
recurrent (Y640F [Pilati et al., 2011], N647I, D661Y [Jerez et al.,
2013], and A662V) missense substitutions (exon 21). JAK1muta-
tions were mostly selected to affect the 1097 (G1097D/S) codon
within the KD of JAK1 (Figure 1D). A proline substitution of JAK1
in position 910 (L910P) was observed in a single case, harboring
both G1097D/S JAK1 and Y640F STAT3 mutations (Figure 1D).
JAK2 and JAK3 were in germline configuration in all samples.
Among PTCLs, JAK1 and STAT3 mutations were specific for
ALK ALCL, and no somatic mutations were present in either
ALK+ ALCL or in PTCL-NOS, including 16 CD30-positive
PTCL-NOS, which share morphological and phenotypic features
with ALK ALCL. STAT3 and JAK1 mutations were absent in
highly purified CD3+CD4+, CD3+CD8+, and CD3CD16+ normal
cells derived from healthy individuals (DSA, 103).
Nuclear pSTAT3 expression, with a staining pattern similar to
that of ALK+ ALCLs, was observed in a fraction of ALK ALCLs
(43% [27 of 63]; Figures 1E and S1). As predicted, all JAK1/
STAT3-mutated ALK ALCLs were found to have strong nuclear
pSTAT3 staining. Nonetheless, a subset of pSTAT3-positive
ALK ALCLs displayed no recurrent JAK/STAT3 mutations
(74% [20 of 27]), suggesting alternative mechanisms for the
constitutive activation of STAT3 (Figure 1E; Table S4). The role
of the JAK/STAT pathway in ALCL was further strengthened by
the gene set enrichment analysis (GSEA) of T cell-associated
STAT3 genes (Piva et al., 2010) in both ALK+ and ALK ALCL
samples (GSEA false discovery rate [FDR] respectively q <
0.001 and q < 0.07; Figure 1F) and by the preferential expression
of STAT3-regulated genes (30%; Figure S1), suggesting that
ALK ALCL may include a subset characterized by the constitu-
tive activation of STAT3.(B) Chromosome view of ALCL genes scoring at the top of mutated genes in regi
del-mut). Each color represents a different tier: red, 1; green, 2; and blue, 3.
(C) Prevalence of the JAK1, STAT3, and JAK1/STAT3 somatic mutations in syst
(D) Schematic representation of human STAT3 and JAK1 proteins with their functio
as single (blue dots), dual (red dots), and triple (green dots) defects in system
sequencing.
(E) Expression of STAT3 by immunohistochemistry in systemic ALK ALCL. The
(F) GSEA of STAT3 gene targets in ALK+ ALCL patient samples versus normal re
(G) GSEA of STAT3 gene targets in ALK ALCL patient samples versus normal r
See also Figure S1 and Tables S1–S4.STAT3 Mutants Are Constitutively Phosphorylated and
Oncogenic
To assess the properties of ALCL-related STAT3 mutants, two
different STAT3/ mouse embryonic fibroblast (MEF) cell lines
were transduced with encoding WT or the mutated (Y640F,
D661Y, and A662V, in brief as YF, DY, and AV) STAT3 viruses
(Figures 2A and S2). The K658Y (in brief as KY) STAT3, aberrantly
expressed in other human cancers, was included for compari-
son. Puromycin-selected cells were cultured in low serum with
or without recombinant interleukin-6 (IL-6). As shown in Fig-
ure 2A, YF and KY STAT3 cells displayed high levels of Tyr705
pSTAT3 (and Ser727; Figure S2), which were further increased
after IL-6 stimulation. Although the IL-6 receptor engagement
led to detectable pSTAT3 in all conditions, YF and KY STAT3
cells displayed robust activation. Similar data were seen in
both STAT3/ MEF cell lines and replicated in human cell lines
carrying WT STAT3 (human embryonic kidney 293T [HEK293T],
lung [A549], and prostate [DU145]) and murine Lewis lung carci-
noma lines (Figures 2B and S2). Conversely, the changes in the
phosphorylation status of other signaling adaptors might be
related to IL-6 exposure and/or the individual phenotypes (Fig-
ures 2A, 2B, and S2). Because lymphokine-mediated signaling
plays a critical role in the maintenance of neoplastic phenotypes
(Ngo et al., 2011; Zhang et al., 2012), we tested the phosphory-
lation status of WT and mutated STAT3 cells after a short IL-6
stimulation. As shown in Figure 2C, levels of WT pSTAT3
decreased over time; in contrast, YF pSTAT3 remained stable.
Similarly, the mRNA transcript of SOCS3, a known STAT3-regu-
lated gene, mirrored the phosphorylation of WT and YF STAT3
cells after IL-6 stimulation (Figure S2).
Thereafter, we sought to demonstrate the oncogenic potential
of mutated STAT3. YF STAT3 MEF displayed the largest number
colonies (Figure 2D) and when injected via tail vein in NOD scid
gamma (NSG) mice, produced lung metastases (Figure 2E),
eventually killing the mice 5 to 6 weeks after implantation,
whereas AV STAT3 andWT STAT3 or STAT3/ control mice re-
mained healthy at 9 weeks.
These findings demonstrated that the non-synonymous ALCL
somatic mutations of STAT3 can sustain cell transformation and
that the activation status of STAT3 is enhanced by lymphokine
signaling activation.
JAK1Mutants Lead to the Constitutive Phosphorylation
of STAT and Synergize with STAT3 Mutants
Next we tested whether the ectopic expression of JAK1mutants
(G1097D and/or S and L910P, in brief GD, GS, and LP) could
lead to constitutive pSTAT. ALCL-associated mutants of JAK1
were associated with high levels of pSTAT3 (Figure 3A). Onceons of focal and recurrent amplifications/deletions (respectively, amp-mut and
emic ALK ALCL and cALCL by Sanger DNA sequencing.
nal domains. Symbols depict distinct types of substitutionmutations occurring
ic and cutaneous ALCL. Individual mutants were validated by Sanger DNA
black scale bar represents 50 mm and the red scale bar represents 20 mm.
sting and activated T cells (GSE6338, GSE14879, and GSE19069).
esting and activated T cells.
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Figure 2. Signaling and Oncogenic Role of Mutated STAT3
(A) Immunoblotting from whole-cell lysates of reconstituted STAT3/ MEF cells.
(B) Immunoblotting from whole-cell lysates of reconstituted human lung adenocarcinoma A549 cells.
(C) Immunoblotting from whole-cell lysates of reconstituted STAT3/ MEF with WT or YF STAT3 constructs after human IL-6 stimulation and its neutralization
with specific antibodies against human IL-6. The relative ratio pSTAT3/STAT3 (P-S/S) is indicated.
(legend continued on next page)
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co-expressed with WT STAT3 in STAT3/ MEF cells, a low
amount of JAK1 mutants resulted in a stronger phosphorylation
of STAT3 compared with WT JAK1 (Figure 3B). Moreover, higher
levels of pJAK1 and pSTAT3 were seen in MEF ectopically co-
expressing both JAK1 and STAT3 mutant proteins (Figures 3C
and S3).
To test the oncogenic potential of double JAK/STAT mutants,
we first performed an in vitro colony assay. Unexpectedly, the
co-expression of LP JAK1 with YF or KY STAT3 (but not with
WT) cassettes led to cell death (data not shown). Because GD
JAK1 and DY STAT3 were most frequently detected in ALK
ALCLs, we focused on these associations. GD/S JAK1 and DY
STAT3 double-mutant cells displayed higher number of colonies
compared with GD/S JAK1 alone and/or JAK1 GD/S and WT
STAT3, suggesting a synergistic role of these proteins (Figures
3D and S3). Because MEFs may not represent the best model
to test mutations associated with neoplastic T cells, we forced
the expression of single JAK1 or STAT3 in SUMP-M2, reasoning
that ALK+ ALCLs are totally dependent on STAT3 signaling and
are most related to ALK ALCL (Piva et al., 2010). Control and
transduced cells were treated with a selective ALK TKi and alive
cells were enumerated. As shown in Figure 3E, the TKi exposure
led to the total cell death of control and WT JAK1 or STAT3 cells.
Conversely, both GD JAK1 and YF/DY STAT3 cells were partially
rescued, while double-positive elements were salvaged. Inter-
estingly, when an equal number of single transfected GD JAK1
and DY STAT3 were co-cultured, only 50% of them were alive
at 96 hr, a value similar to that of DY STAT3. These later findings
indicate that independent clones within the samemicro-environ-
ment do not support each other. Last, the concomitant expres-
sion of GD JAK1 and DY STAT3 in lymphocytes from normal
individuals was proved to favor the in vitro expansion as single
mutants enhanced the cell growth of natural killer T (NK/T) cells
in low interleukin-2 (IL-2) concentration (Figure S3).
Then, we evaluated the therapeutic feasibility of STAT3
or JAK1/2 inhibitors. We initially studied WT and YF STAT3
cells exposed to niclosamide, a molecule capable of inhibiting
STAT3 signaling (Li et al., 2013). WT STAT3 cells treated with
increasing amount of the drug displayed lower pSTAT3 levels,
whereas after 48 hr of exposure, the highest non-toxic dose
of niclosamide had a limited effect in YF STAT3 MEF (Figure 3F).
Ruxolitinib, an inhibitor of JAK1/JAK2molecules and the PUH71,
a Hsp90 inhibitor, rapidly abrogated STAT3 phosphorylation
(Figure 3G). As expected, the treatment with PUH71 led to
JAK1 protein downregulation, consistent with an increased
degradation of the active JAK/STAT complex. Drug exposure
was associated with a decreased cell proliferation (Figure 3H)
and a smaller number of colonies in agar (Figure S3) in the
absence of apoptosis (data not shown). Last, to assess the
efficacy of human dose equivalent of ruxolitinib, we took advan-
tage of a patient-derived tumorgraft (PDT) line (ALCL-2 PDT)
generated from a primary ALK ALCL carrying both JAK1
and STAT3 mutations. Lymphoma-bearing mice treated for 14(D) Colony assay in reconstituted STAT3/ MEF cells.
(E) Soft agar colony assay in reconstituted STAT3/ MEF cells.
(F) Histology and phospho-STAT3 expression by immunohistochemistry in mice
1.5 mm, the green scale bar represents 10 mm, and the black scale bar represen
See also Figure S2.consecutive days showed a significant tumor growth inhibition
compared with vehicle-treated animals (Figure 3I). Overall, these
data demonstrate that the pharmacological inhibition of JAK/
STAT pathway represents a viable strategy inmolecular stratified
ALCL.
The Deregulated Expression of STAT3 Leads to the
Upregulation of ATF3
Togain additional dataon themechanism(s) drivingSTAT3-medi-
ated transformation, we analyzed the transcriptome of reconsti-
tuted STAT3 MEF/ cells. An unsupervised clustering analysis
showed that YF and KY STAT3 cells had similar signatures
comparedwith AV andDY STAT3 or controlMEF (Figure 4A). Ca-
nonical STAT3 genes were preferentially enriched in YF and KY
STAT3 cells (Figure 4B), even in the absence of IL-6 stimulation
(Table S5). GSEA showed a significant enrichment in YF STAT3
MEF (GSEA normalized enrichment score = 1.89, FDR < 0.001;
Figure 4C), and a pathway enrichment analysis identified addi-
tional signals, some of which have been linked to STAT3 activa-
tion (Figure 4D). Among STAT3 genes in MEF, we found a set of
transcripts modulated by the knock-down (kd) of ALK and/or
STAT3 in NPM-ALK ALCL cells. These included members of the
AP1 transcription factor family, co-activators and co-repressors
(Figure S4). We focused on ATF3, which has a bifunctional role
contributing to cell transformation (Yin et al., 2008). GSEA
showed a statistical enrichment of ATF3-regulated genes (Table
S6) in YF and KY STAT3 MEF as well as in ALK+ ALCL cells, as
determined by a STAT3 kd (Figure 4E). These data were further
confirmed by the statistical enrichment of ATF3 genes in NPM-
ALK cells, documented by genomic or pharmacological kds of
ALK (Figure 4E). The relationship between pSTAT3 and ATF3
protein expression was then documented in NPM-ALK Karpas
299 cells treated with an ALK inhibitor (CEP28122; Figure 4F)
and after IL-2 withdrawal of NK/T cells (Figure 4G).
Next, we proved that the transformation events associated
with JAK/STAT3 mutants were mediated by a canonical STAT3
signaling pathway. As shown in Figure 4H, the forced expression
of YF and KY STAT3 in STAT3/MEF cells led a robust transac-
tivation of a STAT3-driven luciferase reporter construct. A domi-
nant-negative form of STAT3 (Y795F) and a high amount of WT
STAT3 could inhibit the transactivation of STAT3 mutants in a
dose-dependent manner (Figure S4). Strong luciferase activa-
tion was also seen in transiently transfected STAT3/MEF cells
with increasing amount of GD and LP JAK1 and STAT3 mutants
(Figure 4I), suggesting a cooperative effect of JAK1 and STAT3
mutants.
ALK– ALCLs Express Dual Chimera Derived from
Transcriptional Regulators and Tyrosine Kinases
To identify additional genetic defects in ALCL and to discover
new mechanisms responsible for the constitutive activation
of STAT3, we implemented a bioinformatics analysis of whole-
transcriptome sequencing (RNA sequencing [RNA-seq]) of 23injected with reconstituted STAT3/ MEF cells. The red scale bar represents
ts 20 mm.
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Figure 3. Signaling and Oncogenic Role of Mutated JAK1
(A) Immunoblotting from whole-cell lysates of transfected HEK293T cells.
(B) Immunoblotting from whole-cell lysates of STAT3/ MEF cells, cotransfected with WT STAT3 and mutated JAK1 cassettes. The absolute ratio
pSTAT3/STAT3 (P-S/S) is indicated.
(C) Immunoblotting fromwhole-cell lysates of STAT3/MEF cells cotransfected with YF STAT3 andmutated JAK1 cassettes. The absolute ratio pSTAT3/STAT3
(P-S/S) is indicated.
(legend continued on next page)
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ALK+/ALK ALCLs. A total of 28 fusions were identified and vali-
dated (Figures 5A and S5), including 4 NPM-ALK and 1 TRAF1-
ALK (Abate et al., 2014a) chimeras in the five ALK+ cases. 4 of 18
ALK ALCLs displayed fusion transcripts involving tyrosine ki-
nases (TKs) known to play a pathogenetic role either in hemato-
logic or solid neoplasms (Shaw et al., 2013) (Figure 5B), with 2
ALCLs bearingmore than one fusion (Table S7) all in the absence
of JAK1 or STAT3 mutations. Several samples shared the same
kinase fusions, albeit fused to different partners, suggesting a
non-random event (Figure 5B). All TKs underwent recombination
with partners capable of providing homo- or hetero-dimerization
domains. At their 50-NH2 terminus, three chimeras showed
sequences corresponding to transcription factors or transcrip-
tional repressors (Figure 5C). These included samples express-
ing hybrid transcripts in which the coding region of the NFkB2
(exons 1–13/16) was fused to the intracytoplasmic domain of
ROS1 (NFkB2-ROS1) or TYK2 (NFkB2-TYK2), respectively (Fig-
ures 5D and 5E). The 50 end of both NFkB2 fusions predicted the
expression of proteins with the RHD, NLS, and GRR domain,
lacking all (13–24) or most (16–24) of the ankyrin region of
the NFkB2 (Figure 5C). Loss of the NFkB2 ankyrin region is
necessary for the translation of constitutively active NFkB-fusion
proteins and for its oncogenic role (Neri et al., 1991). Previously
reported NFkB2 translocations included ectopic genomic re-
gions capable of stabilizing the expression of NFkB2 proteins
but lacked alternative coding segments. Within the discovery
panel, two additional samples displayed chimera involving either
ROS1 or TYK2. In case GSP99, the 50 region of NCOR2 was
fused to the intracytoplasmic region of ROS1 (NCOR2-ROS1),
while in case GSP50, PABPC4 was fused to the intra-cyto-
plasmic domain of TYK2 (PABPC4-TYK2) (Figure 5C). NCOR2
is a transcriptional repressor and aberrations altering the
SMRT and N-CoR complex have been associated with meta-
bolic defects and cancers (Privalsky, 2004).
NFkB2-TK Fusions Are Oncogenic and Lead to the
Constitutive Activation of STAT3
Because the N terminus of NFkB provides a domain capable of
homo- or hetero-dimerization, we speculated that NFkB2-TK
could dimerize and undergo trans-phosphorylation. To test this
hypothesis, we first transfected the cDNA of NFkB2-ROS1 into
HEK293T cells (Figure S5). A constitutive tyrosine phosphoryla-
tion was documented in NFkB2-ROS1 and NPM-ROS1 cells, but
not in NFkB2-ROS1 dead mutant HEK293T cells. The NPM-
ROS1 cassette encoded a control fusion protein in which the
50-NPM provides a dimerization domain (Figures 6A and S5).
The ectopic expression of NFkB2-ROS1 and NPM-ROS1 was
associated with the phosphorylation of JAK (JAK2-3) and
STAT3, but not of other signaling cascades (Figure S7). Similar(D) Colony assay in infected STAT3/ MEF cells.
(E) Viability assay of SUP-M2 transduced cells with WT or mutated JAK1 and/or W
96 hr. All values were normalized to untreated control cells.
(F) Immunoblotting from whole-cell lysates of transduced STAT3/ MEF cells tr
(G) Immunoblotting from whole-cell lysates of transduced STAT3/ MEF cells t
(H) Cell growth of reconstituted STAT3/ MEF cells treated with ruxolitinib. The
(I) Tumor growth of mutated JAK1/STAT3 ALCL PDT treated in vivo with vehicle (1
indicated. Values correspond to the mean ± SD.
See also Figure S3.data were obtained in cells transfected with NFkB2-TYK2,
NCOR2-ROS1, and lung-associated ROS1 fusions (Figures
6B–6D). Genetic inhibition of the TK domain of these fusions
throughmutations of the ATP binding pocket (K to F) did not elicit
the phosphorylation of NFkB2 fusions and their downstream
adaptors/molecules (Figure 6).
We next treated EZR-, CD74-, TPM3-, and SDC4-ROS1 cells
with either crizotinib or TAE684, known to inhibit lung-associated
ROS1 fusions, or an anti-ROS1 (JNJ-ROS1i-A) small molecule
(see Supplemental Information) demonstrating a robust inhibi-
tion of phosphorylation of these fusions (Figure S7). Unexpect-
edly, crizotinib and TAE684 did not inhibit NFkB2-ROS1 or
NCOR2-ROS1, whose phosphorylation was however abrogated
by the JNJ-ROS1i-A inhibitor (> 250 nM; Figure S7).
To gain further information of the properties of these new fu-
sions, we studied the half-lives of NFkB2-ROS1 and TYK2 pro-
teins (>36 hr) demonstrating that these fusions could undergo
proteasome independent proteolitic cleavage (data not shown).
Notably, the inhibition of the tyrosine activity of NFkB2-ROS1
enhanced this phenomenon, suggesting that the kinase activity
contributes to the NFkB2-ROS1 protein stability (Figure S7).
NFkB2-ROS1 and NFkB2-TYK2 Are Chimeric
Transcription Factors
Using a cell fractionation assay, we demonstrated that NFkB2
and NCOR2 fusions localized into the nucleus and cytoplasm
and that NCOR2-ROS1 and NFkB2-TYK2 proteins had a similar
distribution (Figure 6E). These findings were corroborated using
an immunofluorescence staining. Last, we showed a restricted
expression in the cytoplasm of an arginine/lysine-rich NLSs
mutant form of NFkB2-ROS1 (DNLS-NFkB2-ROS1) (Figures 6F
and S6), which indicates that an importin-mediated transfer is
required for NFkB2-ROS1 to entry into the nucleus.
Cotransfection of HEK293T with NFkB2-ROS1, NFkB2-ROS1
kd, and a known activated form of NFkB2 (Lyt-10-7) (Neri et al.,
1991) vectors in the presence of an IgK-HIV-kB-driven luciferase
reporter construct led to a dose-dependent luciferase expres-
sion with values higher than those seen in Lyt-10-7 transfected
cells, whereas catalytic dead mutants were less active. This
suggests that the kinase activity of the fusions can contribute
to their transcriptional activity (Figures 6G–6H). We then proved
that Rel-B could increase NFkB2-ROS1-mediated transcription,
whereas p50 or p65 had no major effects (data not shown).
Last, knowing that Rel/NFkB transcription factors lead to the
selective expression of different target genes, we studied the
transcription of Lyt10, NFkB2-ROS1, NFkB2-ROS1 kd, and
NPM-ROS1 in HEK293T cells. Only a fraction of NFkB2-ROS1
upregulated genes were overlapping to NPM-ROS1 or NFkB2-
ROS1 kd; meanwhile, NFkB2-ROS1 cells displayed a uniqueT or mutated STAT3 treated with CEP28122 (50 nM, daily [with or without]) for
eated with niclosamide
reated with ruxolitinib and PUH71.
p value (*p < 0.01) is indicated. Values correspond to the mean ± SD.
2 tumors) or ruxolitinib (8 tumors, 25 mg/kg for 14 days). Treatment schedule is
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Figure 4. Gene Transcriptional Activation of Mutated STAT3
(A) Unsupervised hierarchical clustering of top 100 genes with higher variance of expression across the control and reconstitute STAT3/MEF cells: backbone
vector (pLentiPGKpuroDEST, in brief DEST), WT, AV, DY, KY, and YF STAT3 cassettes. Control (nil) cells are included. Cells were cultured in low serum or in the
presence of recombinant human IL-6 (50 ng/ml for 30 min).
(legend continued on next page)
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set of genes (Figure 6J). To elucidate the contribution of addi-
tional pathways, we performed a C2-GSEA demonstrating that
NFkB2-ROS1 fusion elicits the expression of genes involved in
membrane trafficking, replication, protein export, TNF signaling,
T cell activation (Figure S6). This result suggests that NFkB2-
ROS1 signature is not merely due to the individual contribution
of NFkB2 and ROS1 signaling.
Last, to infer of the relative frequency of NFkB2-ROS1 fusions,
we stained a set of ALCLs with an antibody detecting a formalin-
resistant epitope of ROS1. ROS1-positive ALCL cells (2 of 100
ALCLs known to carry ROS1 fusions; Figure 5F) displayed nu-
clear staining for pSTAT3. Expression data confirmed these
data (Figure S5), in agreement with a recent study (Velusamy
et al., 2014). Nevertheless, molecular and fluorescence in situ hy-
bridization analyses on large PTCL patient cohorts are required
to conclusively assess the frequency of these fusions.
NFkB2-TK and NCOR2-ROS1 Are Tumorigenic and
Require STAT3 Signaling
To test the oncogenic activity in vitro of ALK ALCL-associated
fusions, we transfected mouse 3T3 fibroblasts. Within 2 weeks,
NFkB2-ROS1, NFkB2-TYK2, and NCOR2-ROS1 cells had es-
tablished a larger number of colonies compared with kd-
matched constructs or untrasfected cells (Figures 7A and S7).
However NPM-ALK cells had the highest transformation poten-
tial. Once NFkB2-ROS1 and NFkB2-ROS1 kd NIH 3T3 cells
were injected subcutaneously (s.c.) into NSG mice, they pro-
duced tumors, although NFkB2-ROS1 cells grew faster and
reached larger masses overtime. No mice injected with parental
cells developed tumors (4-weeks after injection; Figure 7B). To
dissect the tumorigenic role and the dual function of the NFkB2-
ROS1 chimera in vivo, NFkB2-ROS1 NIH 3T3-bearing NSGmice
were treated with JNJ-ROS1i-A, showing a growth inhibition of
NFkB2-ROS1 cells (Figure 7C).
To investigate a potential role of STAT3, we first forced the
expression of NFkB2-ROS1, NFkB2-TYK2 and NCOR-ROS1 in
STAT3/ MEF cells. Contrary to WT STAT3 MEF cells, ROS1
and TYK2 fusions in STAT3/ MEF cells led only to a slightly
larger number of colony compared to control (Figure S7), sug-
gesting a strict requirement for STAT3-mediated transformation,
likewise as for ALK chimera (Chiarle et al., 2005).
Although in vitro models have been instrumental to elucidate
the tumorigenic properties of oncogenes, these assays do not
fully recapitulate the oncogenic properties of specific lesions
operating in different lineages. Because ROS1 fusion expression
in activated human T cells led to senescence (data not shown),
we tested whether NFkB2-ROS1 could rescue the cell death of(B) Log2 fold change of genes belonging to STAT3 target genes (up- and downre
STAT3/ MEF cells. All fold changes are computed versus empty vector STAT3
(C) GSEA of STAT3 gene targets in YF STAT3 cells versus control (nil, DEST) ST
(D) Heatmap of overrepresented pathways among up- and downregulated genes i
by hypergeometric p values.
(E) GSEA of ATF3 target genes: YF STAT3 mutant versus STAT3/ MEF (upper
versus doxycycline-induced ALK shRNA NPM-ALK (lower left); untreated versus
(F) Immunoblotting from whole-cell lysates of NPM-ALK ALCL cells (Karpas 299
(G) Immunoblotting from whole-cell lysates of NKL cells supplemented with (20
(H and I) Luciferase expression of cells with single- or double-transfected STAT3
correspond to the mean ± SD.
See also Figure S4 and Tables S5 and S6.ALK+ ALCL cells after ALK kd signaling. Taking advantage of
the resistance of ROS1 fusions to crizotinib and CEP28122
ALK Ki, we infected SUP-M2, SU-DHL-1, and JB-6 NPM-ALK
ALCL cells with NFkB2-ROS1 or control vectors (Figure S7).
The kd of ALK signaling using CEP28122 or an inducible ALK
RNAi was associated with growth inhibition and loss of viability,
changes largely overcome by the forced expression NFkB2-
ROS1 but not in NFkB2-ROS1 kd (Figures 7D and S7).
We then tested the role of STAT3 in NFkB2-ROS1 signaling in
these models. NFkB2-ROS1, NFkB2-ROS1 kd, or NPM-ROS1
were introduced in S3S SUP-M2-TS cells, in which STAT3
mRNA levels are controlled by a doxycycline-inducible RNAi
system. As expected, loss of STAT3 in control cells led to cell
death (>120 hr), a phenotype that could not be rescued by
NFkB2-ROS1 signaling. Overall, these findings demonstrated
that NFkB2-ROS1 can rescue ALK oncogenic addiction and
that the STAT3 signaling is required for NFkB2-ROS1-mediated
rescue (Figures 7D and 7E).
Last, we investigated the signaling pathway of NFkB2-TYK2.
We demonstrated that its ectopic expression led to the robust
activation of pSTAT1 and/or /3/5 in Jurkat, HEK293T, and MEF
cells (Figures 7G and S7) and pSTAT could be inhibited by a
selective JAK/TYK2 inhibitor (Chrencik et al., 2010; Sanda
et al., 2013) and by a specific small hairpin RNA (shRNA)
(Figures 7G and S7). Conversely, NFkB2-TYK2 in ALK+
ALCL cells did not modulate either pSTAT1 or pSTAT5 levels
(Figure 7H).
DISCUSSION
We provide molecular and biological data demonstrating that a
subset of systemic ALK ALCLs and cutaneous ALCLs display
the constitutive activation of the JAK/STAT3 pathway via multi-
ple and alternative genomic mechanisms. Mutually exclusive
oncogenic mutations of JAK (Bellanger et al., 2014) and STAT
have been reported in several human cancers (Odejide et al.,
2014; Pilati et al., 2011) and in some CD30-positive lymphopro-
liferative disorders (Ohgami et al., 2013). Our study provides a
paradigm, demonstrating the presence of concomitant muta-
tions on the JAK/STAT3 pathway in human cancers. Functional
tests of JAK1 and STAT3mutants showed that individual aberra-
tions could cooperate when co-expressed. Treatment with a
JAK1/2 and Hsp90 inhibitors was associated with growth inhibi-
tion of reconstitute YF STAT3 MEF cells. An in vivo PDT model
derived from a double JAK/STAT3 mutant ALK ALCL patient
corroborated this finding. We have also identified TK fusions
derived from the juxtaposition of transcription/repressor factorsgulated) and the remaining genes in DEST, AV, DY, and YF STAT3 reconstitute
/. The p values were calculated with the Wilcoxon rank sum test.
AT3/ MEF.
n YF/KY STAT3 and AV/DY STAT3MEF cells. Pathway enrichment is measured
left); non-induced versus STAT3 shRNA NPM-ALK (upper right); non-induced
CEP14823 treated NPM-ALK cells (lower right).
) treated over time with an anti-ALK inhibitor (CEP28122).
ng/ml) or without human recombinant IL-2.
/ MEF cells. The p values (*p < 0.01 and **p < 0.001) are indicated. Values
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Figure 5. Strategy and Discovery of Chimeric Fusion in ALK– ALCL
(A) Schematic representation of RNA-seq data gene fusion analysis.
(B) Circos plot showing validated intra- and inter-chromosomal gene fusions. Gene fusions undergoing functional validation are depicted with red links. Different
gene fusions exchange gene partners, suggesting a non-random pattern.
(legend continued on next page)
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to TKs, whose oncogenic properties rely on the STAT3 signaling
pathway. Interestingly, rare fusions were described in human
cancers (Shern et al., 2014) and in a subset of CD30 lymphopro-
liferative disorders of the skin (Velusamy et al., 2014). A compre-
hensive map of the different lesions found by next-generation
sequencing demonstrate that the majority of the ALK ALCL
bear driver mutations, but no bona fide drivers could be recog-
nized in some tumors.
The deregulated expression of STAT3 is commonly seen in
human cancer, and pro-oncogenic STAT3 mutations have
been described in some neoplasms and are required for the
maintenance of the ALK+ ALCL phenotype (Chiarle et al.,
2005). We found that in ALK ALCL, JAK1 and STAT3mutations
most commonly occurred in hot spots, with an exception repre-
sented by the mutation of JAK1 in L910P. When different STAT3
mutants are coexpressed with L910P JAK1 cells undergo cell
growth arrest and ultimately senescence, suggesting that a
non-random association of specific mutations may occur. In
the case of JAK1, mutations have been reported to arise in
amino acids facing the interface in which the pseudokinase
and kinase interact, resulting in increased kinase activity (Lupar-
dus et al., 2014). However, the residue G1097, which most
frequently mutated in ALCL, is sitting on the surface of the mole-
cule, and it might modulate protein-protein interactions. In the
case of STAT3, mutations commonly occur within the SH2
domain. The residue in position Y640 of STAT3 is near the
TAD domain, which allows protein and DNA interaction.
Changes in the polarity of this residue may stabilize STAT3
dimers, consistent with the prolonged phosphorylation status
of Y640F STAT3.
The association between convergent and recurrent point
mutations in genes coding for two interacting proteins is unex-
pected. First, the distribution of mutations in hot spots points
to gain-of-function mutations in both proteins. Second, and
more surprisingly, the concurrence of these alterations indi-
cates that these double mutants are strongly selected beyond
single mutants. If mutations are randomly distributed along
the genome, and the probability of a single mutation is small,
the probability of double mutations should theoretically be the
square of the probability of having a single mutation. This argues
that these double mutants might undergo very strong selection.
Notably, the possibility that JAK1 and STAT3 mutants could be
present in two independent subcloneswithin the double-positive
samples cannot be conclusively ruled out. However, the deep
sequencing of single double-positive samples and its derived
PDT confirmed that these aberrations were present in heterozy-
gosity in both primary and PDT derived tissue samples, strongly
suggesting that they co-exist.
Our findings showed that mutated STAT3 proteins are potent
transcriptional activators and the constitutive activation of the(C) Gene fusions detected by paired-end massively parallel whole-transcriptom
breakpoints. Intron-exon configuration is depicted: 50 (blue) and 30 (red) partners
variant resulting from the fusions.
(D) PCR amplification products spanning the breakpoints of the fusion of ALK A
(E) DNA sequencing electropherograms of chimeric fusion after PCR from ALK
(F) Immunohistochemistry on a representative sample carrying the NFkB2-ROS
represents 25 mm.
See also Figure S5 and Table S7.JAK1/STAT3 pathway leads to the modulation of a set of genes
in different cells (MEF, ALK+ ALCL, and NKL) and can protect
ALK+ ALCL cells when treated with ALK TKi. This suggests
that STAT3 mediated transformation requires the modulation
of a critical number of genes, including ATF3 and its regulated
targets. Deregulation of ATF3-regulated genes has been linked
to cell transformation (Yin et al., 2008) but never associated
with STAT3 activation in human cancers. Although these data
were largely generated in MEF cells, we have proven that cells
derived from different lineages (MEF, HEK293T, NK and
T cells) co-share STAT3- and/or ATF3-regulated genes. These
data must be confirmed in more reliable ALK ALCL models,
which are currently lacking. The use of PDT derived from
different human PTCLs may overcome in part this limitation.
It is now known that the host plays a critical role in the main-
tenance of the neoplastic phenotype, and IL-6-mediated
stimulation by intratumoral infiltrating lymphocytes has been
proved to be critical in liver disorders (Pilati et al., 2011;
Rebouissou et al., 2009). Here, we have shown that cells car-
rying mutated STAT3 displayed high and prolonged levels of
pSTAT3 after IL-6 stimulation, and this activation is repressed
by inhibiting JAK1/2, suggesting that pSTAT3 of mutated
forms requires JAK1/2. In lymphoma, high levels of lympho-
kines can be provided through an autocrine loop or via host
cells, a scenario also seen in lymphoproliferative disorders
(Anderson, 2007). High expression levels of IL-2 and IL-22
can occur as after the loss of the transcriptional repressor
(i.e., BLIMP1), which is often lost in many ALK ALCLs (Boi
et al., 2013).
The RNA-seq data have provided an additional layer of
complexity for the constitutive activation of STAT3. We had
originally shown that both ALK+ and ALK ALCLs share a
common signature (Piva et al., 2010). Now we provide data
confirming that ALK ALCLs can display a constitutive
pSTAT3 in the absence of either JAK/STAT3 mutations, as a
result of NFkB2-ROS1 and NFkB2-TYK2 fusions. Interestingly,
we demonstrated that NFkB2-TYK2 can lead to pSTAT1/3/5
and that individual STATs can be differentially activated in
different cells. In ALK chimera, the ALK partners contribute
by providing only dimerization domains, lacking oncogenic ac-
tivities, with TRAF-1 being the exception (Abate et al., 2014b).
The scenario is different for NFkB2-ROS1 and TYK2 fusions,
because they are transcriptional active and their transcrip-
tional activity can be enhanced by the enzymatic activity of
the kinases. This may be due in part to the protein stability
of NFkB2-ROS1. However, an alternative scenario may be
taking place, as a result of their translocation into the nucleus
leading to the aberrant phosphorylation of proteins not other-
wise accessible to the native kinases (i.e., transcriptional
holocomplexes). This is partially supported by the uniquee sequencing. Mate-pair sequences are shown, aligning on either side of the
are indicated. Transcribed exonic sequences are shown as part of a transcript
LCL samples (discovery samples).
ALCL samples (discovery samples).
1 fusion, using specific antibodies against pSTAT3 and ROS1. The scale bar
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Figure 6. Signaling, Cellular Distribution, and Transcriptional Activity of NFkB Chimeric Fusion in ALK– ALCL
(A–D) Immunoblotting from whole-cell lysates of transfected HEK293T cells.
(E) Cellular localization of NFkB2-kinase fusions in transfected HEK293T cells after cell fraction.
(legend continued on next page)
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signature of NFkB2-ROS1, which has minimal overlaps to
either NFkB2 or ROS1 profiles.
However, the oncogenic contribution of NFkB is unclear,
because STAT3 is critical for the NFkB2-ROS1-mediated pheno-
type in MEF and in ALK+ ALCL cells. Although the role of NFkB in
B cell neoplasia is well established, its contribution in T cell dis-
orders is less defined. Toward this end, the activation of NFkB
can be seen in both ALK and in ALK+ ALCLs, suggesting that
this pathway can contribute to the lymphoma phenotype (Abate
et al., 2014b).
Many innovative protocols have been explored to improve the
clinical outcome of ALK ALCL or refractory ALK+ ALCL (overall
survival of 35%–40% at 5 years) with limited success. No up-
front biomarkers for refractory or relapsing patients exist, and
refractoriness-driving lesions remain unknown. The recurrent
aberrations (Boi et al., 2013; Parilla Castellar et al., 2014)
need to be tested in prospective cohorts to discern their prog-
nostic clinical significance. Nevertheless, the discovery of
targetable pathogenetic defects provides the rationale for the
triage and selective treatment of molecularly defined ALK
ALCL patients. In fact, the discovery that selective compounds
targeting either JAK or STAT3 can inhibit cell growth offers
alternative therapeutic avenues. As selective STAT3 inhibitors
have not been approved, JAK inhibitors have entered the clin-
ical arena (Sonbol et al., 2013) and could be tested in molecu-
larly stratified ALCL patients, as suggested by our pre-clinical
ALCL PDT model. The central role of STAT3 in these and in
many other types of hematological malignancies urges the
execution of new drug discovery programs and the design of
innovative protocols.
EXPERIMENTAL PROCEDURES
Tissue Samples
Fresh and viable cryopreserved samples from primary lymphoma were ob-
tained at the time of diagnosis or at relapse after chemotherapy. Diagnoses
were assigned according to the World Health Organization classification (Ta-
ble S3). Tissues used for NGS analyses were selected for their high tumor
cell content (>50%). All studies were approved by the institutional human
ethics review board, and patients provided written informed consent in accor-
dance with the Declaration of Helsinki.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry stains of primary lymphoma were implemented on
formalin-fixed paraffin-embedded sections with specific antibodies (Supple-
mental Experimental Procedures). The immunofluorescence was completed
as described (Voena et al., 2013).
RNA Preparation, Quantitative Real-Time PCR, and Microarray
Analysis
Total RNAs were isolated using Trizol reagent (Ambion). Quantitative real-
time PCR analysis was performed using the iQ SYBR Green Real-Time PCR
Supermix (BioRad). Transcript levels were normalized to the a-actin or GAPDH
level. A list of specific primers is available in Supplemental Experimental
Procedures.
Gene expression profiling data were analyzed as previously described (Boi
et al., 2013).(F) Immunofluorescence of chimeric fusions in transfected HEK293T cells using
(G and H) Luciferase expression of transfected HEK293T cells. Values correspon
(I) Heatmap of genes differentially expressed in NFkB2-ROS1, NPM-ROS1, NFK
See also Figure S6.Whole-Exome and RNA-Seq
Whole-exome sequencing and RNA-seq were performed as previously
described (Palomero et al., 2014; Abate et al., 2014b)
Bioinformatics Analysis
Single-nucleotide variants (SNVs) were determined by means of the Statistical
Algorithm for Variant Identification. Copy number variations and SNVs
were integrated with the MutComFocal algorithm, and chimeric transcripts
were detected by deFuse andChimeracan. Pegasuswas used to assign fusion
annotation and functional selection (Supplemental Information). mRNA quan-
tification in RNA-seq data analyses were determined by the Cufflinks package
and GSEA by GSEA pre-ranked tool. Gene expression data had been previ-
ously reported (accession numbers GSE6184, GSE6338, GSE14879, and
GSE19069).
DSA
Purified PCR DNA fragments were obtained after genomic DNA amplification
with primer specific for spanning hot spot mutations/SH2 domains along with
10-bp multiplex identifier tag sequences and high-fidelity Taq polymerase
(FastStart High Fidelity PCR System; Roche Diagnostics). Purified DNA frag-
ments were subjected to ultra-deep NGS on the Genome Sequencer Junior in-
strument (454 Life Sciences).
Multiparametric Assays
Cells were culture in standard conditions. Multiparametric assays were
conducted in 96-well microtiter plates (40,000 cells/well). Cell viability and
Renilla-based luciferase expression were measured using CellTiter-Glo Lumi-
nescent Cell Viability Assay and the Dual-Luciferase Reporter system
(Promega).
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were injected s.c. or intrave-
nously with 1 3 106 cancer cells. For experimental metastasis assays, mice
were sacrificed after 4 to 8weeks after intravenous injection. PDTswere estab-
lished by implanting fresh tissue fragments s.c. PDT mice were treated with
ruxolitinib (100 mg/kg twice daily) and NFKB2-ROS1 NIH 3T3-bearing mice
with the JNJ-ROS1i-A small molecule (20 mg/kg twice daily). The Animal
and Bioethical Committee of the University of Torino (TO-0072468) and the
Institutional Animal Care and Use Committee of Weill Cornell Medical College
(2014-0024) approved the animal protocols.
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